Price$18.28-0.79 (-4.14%)
02:15 PM07:45 PM
News · 26 weeks49+88%
2025-12-142026-06-07
Mix3190d
- Insider16(52%)
- Other7(23%)
- SEC Filings6(19%)
- Earnings2(6%)
Latest news
25 items- INSIDERPresident and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 893,293 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- PRFulgent Presents Updated FID-007 Data at ASCO 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study (NCT0633
- INSIDERPresident and COO Xie Jian sold $21,138 worth of shares (1,201 units at $17.60), decreasing direct ownership by 0.32% to 369,751 units (SEC Form 4) (for withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 364,632 units (SEC Form 4) (tax liability)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERChief Scientific Officer Gao Hanlin sold $16,632 worth of shares (945 units at $17.60), decreasing direct ownership by 0.10% to 992,062 units (SEC Form 4) to cover withholding tax4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
- INSIDERChief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 897,685 units (SEC Form 4) (withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECFulgent Genetics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- PRFulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual MeetingFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020". It presents interim data from th
- INSIDERDirector Nohaile Michael was granted 5,558 shares, increasing direct ownership by 29% to 24,578 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERDirector Dong Linda was granted 11,117 shares, increasing direct ownership by 40% to 38,758 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERDirector Groves Regina E was granted 11,117 shares, increasing direct ownership by 65% to 28,099 units (SEC Form 4)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- SECSEC Form S-8 filed by Fulgent Genetics Inc.S-8 - Fulgent Genetics, Inc. (0001674930) (Filer)
- SECFulgent Genetics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
- PRFoundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent GeneticsNew solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care FoundationOne PGx includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including DPYD Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne®PGx, a pharmacogenetic (PGx) offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics, Inc. (NASDAQ:FLGT) and will be available to order thro
- PRFulgent Reports First Quarter 2026 Financial ResultsReiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% GAAP loss of $24.8 million, or $(0.80) per share; Non-GAAP loss of $11.0 million, or $(0.36) per share Ended the first quarter of 2026 with $604.7 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106 million Fulgent Genetics, In
- INSIDERChief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 0.17% to 993,007 units (SEC Form 4) (withholding tax)4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERPresident and COO Xie Jian covered exercise/tax liability with 4,361 shares, decreasing direct ownership by 1% to 370,952 units (SEC Form 4) to satisfy withholding obligation4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- INSIDERCFO and Treasurer Kim Paul covered exercise/tax liability with 2,747 shares, decreasing direct ownership by 0.75% to 365,800 units (SEC Form 4) to satisfy withholding tax4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
- PRFulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual MeetingFulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)", clinical trial identifier, NCT06332092. This is a Phase 2 study designed to evaluate the efficacy o
- PRFulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a
- INSIDERAmendment: SEC Form 4 filed by Hsieh Ming4/A - Fulgent Genetics, Inc. (0001674930) (Issuer)
FLGT FAQ
7 questionsWhat does Fulgent Genetics Inc. do?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has...Where does FLGT stock trade?
Fulgent Genetics Inc. (FLGT) is listed on NASDAQ.What sector and industry is FLGT in?
Fulgent Genetics Inc. operates in the Health Care sector, Medical Specialities industry.When did Fulgent Genetics Inc. go public?
Fulgent Genetics Inc. (FLGT) completed its IPO in 2016.What are analysts saying about FLGT?
Fulgent Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $3000.00 price target on 2025-08-05. Recent price targets range from $3000.00 to $4500.00.What companies are similar to FLGT?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare FLGT side-by-side with any of them on Quantisnow.How can I track FLGT on Quantisnow?
Quantisnow aggregates Fulgent Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FLGT to receive live email and push alerts on every new disclosure.